Evidence map›Paper›PMID 35835415›Full record

ArticleBiochimica et biophysica acta. Molecular basis of disease2022

Protein kinase D: A therapeutic target in experimental alcoholic pancreatitis.

Jingzhen Yuan, Chintan Chheda, Grace Tan, Omer Elmadbouh, Stephen J Pandol

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta. Molecular basis of disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Acute pancreatitis experimental models, advantages and disadvantages.Journal of physiology and biochemistry · 2025
    Review
  2. Article
  3. Protein kinase D1 - A targetable mediator of pancreatic cancer development.Biochimica et biophysica acta. Molecular cell research · 2024
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jingzhen YuanCedars-Sinai Medical Center, Los Angeles, CA, USA; Veterans Affairs Greater Los Angeles Healthcare System, University of California at Los Angeles and South California Research Center for Alcoholic Liver and Pancreatic Diseases, California, USA. Electronic address: Jingzhen.Yuan@cshs.org.
Chintan ChhedaCedars-Sinai Medical Center, Los Angeles, CA, USA.
Grace TanVeterans Affairs Greater Los Angeles Healthcare System, University of California at Los Angeles and South California Research Center for Alcoholic Liver and Pancreatic Diseases, California, USA; Loma Linda Medical School, Los Angeles, CA, USA.
Omer ElmadbouhCedars-Sinai Medical Center, Los Angeles, CA, USA.
Stephen J PandolCedars-Sinai Medical Center, Los Angeles, CA, USA; Veterans Affairs Greater Los Angeles Healthcare System, University of California at Los Angeles and South California Research Center for Alcoholic Liver and Pancreatic Diseases, California, USA.
Cedars-Sinai Medical Center · USLoma Linda University Medical Center · US

Funding

Targeting protein kinase D in alcoholic pancreatitisR01AA024464 · NIAAA · CEDARS-SINAI MEDICAL CENTER · PI PANDOL, STEPHEN J., YUAN, JINGZHEN · 2016 to 2020
$2.0M
Molecular Mechanisms of Stellate Cell Activation in Liver FibrosisI01BX001991 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI HIDEKAZU TSUKAMOTO · 2014 to 2026
–
NIAAA NIH HHS R01 AA024464
6 · The paper itself

Abstract

backgroundAlcohol abuse, a main cause of pancreatitis, has been known to augment NF-κB activation and cell necrosis in pancreatitis. However, the underlying mechanisms are unclear. We recently reported that inhibition of protein kinase D (PKD) alleviated NF-κB activation and severity of experimental pancreatitis. Here we investigated whether PKD signaling mediated the modulatory effects of alcohol abuse on pathological responses in alcoholic pancreatitis.

methodsAlcoholic pancreatitis was provoked in two rodent models with pair-feeding control and ethanol-containing Lieber-DeCarli diets for up to 8 weeks followed by up to 7 hourly intraperitoneal injections of cerulein at 1 μg/kg (rats) or 3 μg/kg (mice). Effects of PKD inhibition by PKD inhibitors or genetic deletion of pancreatic PKD isoform (PKD3Δpanc mice) on alcoholic pancreatitis parameters were determined.

resultsEthanol administration amplified PKD signaling by promoting expression and activation of pancreatic PKD, resulted in augmented/promoted pancreatitis responses. Pharmacological inhibition of PKD or with PKD3Δpanc mice prevented the augmenting/sensitizing effect of ethanol on NF-κB activation and inflammatory responses, cell necrotic death and the severity of disease in alcoholic pancreatitis. PKD inhibition prevented alcohol-enhanced trypsinogen activation, mRNA expression of multiple inflammatory molecules, the receptor-interacting protein kinase activation, ATP depletion, and downregulation of pro-survival Bcl-2 protein in alcoholic pancreatitis. Furthermore, PKD inhibitor CID755673 or CRT0066101, administrated after the induction of pancreatitis in mouse and rat alcoholic pancreatitis models, significantly mitigated the severity of pancreatitis.

conclusionPKD mediates effect of alcohol abuse on pathological process of pancreatitis and constitutes a novel therapeutic target to treat this disease.

Indexed as

AlcoholismPancreatitis, AlcoholicAdenosine TriphosphateAnimalsCeruletideEthanolMiceNecrosisNF-kappa BProtein Kinase CProto-Oncogene Proteins c-bcl-2RatsRNA, MessengerTrypsinogenAdenosine TriphosphateCeruletideEthanolNF-kappa BProtein Kinase Cprotein kinase DProto-Oncogene Proteins c-bcl-2RNA, MessengerTrypsinogenAlcohol abuseInflammationNecrosisNF-κBPKD3Δpanc micePKD inhibitors

Identifiers

PMID35835415
PMCPMC9481726
OpenAlexW4285045593

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.